Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:ABT), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. What Is Return On Capital Employed (ROCE)? Just to clarify if you're unsure ...

A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies ...

Nov 1 (Reuters) - Abbott Laboratories (ABT.N), opens new tab shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over ...

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a ...

They’re at the center of a legal battle with the makers of specialized formulas for preterm infants — north suburban-based Abbott Laboratories and Indiana-based Mead Johnson Nutrition — that ...

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $130.00. Rick Wise has given his Buy rating due to a ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...